{"classes":[{"categories":[{"measurements":[{"comment":"The median and 95% confidence interval were not estimable due to very less number of participants with events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"Overall survival (OS) was defined as the time from the date of the initial dose of study intervention to the date of the participant's death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with androgen receptor (AR) expressing locally advanced or recurrent/metastatic salivary gland carcinoma (SGC) received apalutamide 240 milligrams (mg) (4\\*60 mg tablets) orally once daily with or without food in combination with stable regimen of goserelin 3.6 mg administered subcutaneously once per cycle (each cycle is of 28 days) as a gonadotropin-releasing hormone (GnRH) agonist, until disease progression, unacceptable toxicity, death, or end of the study.","id":"OG000","title":"Apalutamide + Goserelin"}],"paramType":"MEDIAN","populationDescription":"Treated analysis set included all participants who received at least 1 dose of study intervention.","reportingStatus":"POSTED","timeFrame":"Up to 13 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}